Loading...
•
Jun 30, 2023
Aura Biosciences Q2 2023 Earnings Report
Reported financial results for the second quarter ended June 30, 2023, and provided clinical development and operational highlights.
Key Takeaways
Aura Biosciences reported its Q2 2023 financial results, highlighting ongoing global Phase 3 trial start-up activities and key leadership appointments. The company's cash and cash equivalents totaled $162.0 million, expected to fund operations into the second half of 2025. The first patient is expected to be dosed in the second half of 2023
Global start up activities for the Phase 3 trial are ongoing.
Aura released the commercial process material for the global Phase 3 trial.
Enrollment is complete in the Phase 2 trial evaluating SC administration of bel-sar for the first-line treatment of adult patients with early-stage choroidal melanoma (CM).
The Phase 1 trial of bel-sar for the treatment of non-muscle invasive bladder cancer (NMIBC) is currently ongoing, and Aura expects to report data in 2024.
Forward Guidance
Aura believes its current cash and cash equivalents and marketable securities are sufficient to fund its operations into the second half of 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...